Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
2.185
+0.175 (8.71%)
At close: Apr 17, 2025, 4:00 PM
2.170
-0.015 (-0.69%)
After-hours: Apr 17, 2025, 5:09 PM EDT
Aldeyra Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Aldeyra Therapeutics stock have an average target of 9.67, with a low estimate of 9.00 and a high estimate of 10. The average target predicts an increase of 342.56% from the current stock price of 2.19.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aldeyra Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Maintains $11 → $9 | Strong Buy | Maintains | $11 → $9 | +311.90% | Apr 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +357.67% | Apr 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +357.67% | Mar 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +357.67% | Aug 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +357.67% | Aug 2, 2024 |
Financial Forecast
Revenue This Year
n/a
from 175.91M
Revenue Next Year
n/a
EPS This Year
-0.11
from -0.94
EPS Next Year
-0.59
from -0.11
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 179.5M | 144.4M | 138.4M | ||
| Avg | 59.4M | 49.9M | 101.7M | ||
| Low | n/a | 12.7M | 49.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.0% | 143.2% | 177.3% | ||
| Avg | -66.2% | -16.0% | 103.8% | ||
| Low | - | -78.5% | -0.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.79 | -0.43 | 0.74 | ||
| Avg | -0.11 | -0.59 | 0.18 | ||
| Low | -1.05 | -0.67 | -0.22 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.